Clinical Trial Update: Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing alogliptin to acarbose in Chinese patients with type 2 diabetes and high cardiovascular risk on aspirin and inadequate metformin contr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Acarbose (acarbose)
• Alogliptin (alogliptin)

Snippet

Sponsor: Sanofi | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED